Gradient Denervation Technologies
Manufacturing · France · 1-10 Employees
View Company Info for Free
Overview
Headquarters
9 Rue D'enghien, Paris, Ile-de-France, 7...Website
www.gradientdenervation.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Gradient Denervation Technologies
Gradient Denervation Technologies is a Paris-based medical device company focused on developing a minimally invasive, ultrasound-based system for treating pulmonary hypertension, particularly in patients with left-sided heart disease. Their innovative Gradient Denervation System utilizes therapeutic ultrasound energy to ablate nerves around the pulmonary artery, addressing a significant clinical need in a patient population with limited treatment options. The company leverages intellectual property developed at Stanford University and aims to transform the treatment landscape for pulmonary hypertension. Their target clients include healthcare providers and patients suffering from pulmonary hypertension due to heart failure.Explore more
Gradient Denervation Technologies Org Chart
GM
Chief Financial Officer
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Gradient Denervation Technologies your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Gradient Denervation Technologies, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Gradient Denervation Technologies has recently received funding, and reach out quickly before it becomes old news!
Check out if Gradient Denervation Technologies is spiking on competitors!
Product Launch: Get notified when Gradient Denervation Technologies launches new products
Funding: Get notified immidiatlly once Gradient Denervation Technologies has new funding data
Congratulate Masked Content for being promoted to Masked Content at Gradient Denervation Technologies
Click to see if Gradient Denervation Technologies had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Gradient Denervation Technologies recently announced quarterly report
Recommended Actions
Find VP level buyers at Gradient Denervation Technologies
Find 3 more new buyers
Company Profile Activity
Activity Insights
Gradient Denervation Technologies is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Gradient Denervation Technologies is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Gradient Denervation Technologies.
Gradient Denervation Technologies financials insights
Gather financial insights about Gradient Denervation Technologies, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2023
Series A
$15M
Gradient Denervation Technologies Tech Stack
A closer look at the technologies used by Gradient Denervation Technologies
See more technologies
Gradient Denervation Technologies News & Media
Gradient Denervation Technologies Announces FDA Breakthrough Designation for Pulmonary Artery Denervation System
PARIS, May 19, 2025 (GLOBE NEWSWIRE) -- Gradient Denervation Technologies announced today the company’s pulmonary denervation system has received Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA). This program creates an expedited review pathway for devices that have the potential to provide more effective treatment for life-threatening or debilitating conditions and meet FDA’s rigorous standards for safety and efficacy.Gradient Denervation Technologies Appoints Stanton Rowe to Board of Directors and Receives FDA Approval to Expand Early Feasibility Study
Serial entrepreneur and medical device industry executive adds key experience to board of directors Serial entrepreneur and medical device industry executive adds key experience to board of directorsGradient Denervation Technologies Enrolls First Patient in Early Feasibility Study of Pulmonary Artery Denervation System
FDA-Approved US study intended to evaluate pulmonary artery denervation in heart failure patients with WHO Group 2 Pulmonary Hypertension PARIS, March 6, 2024 /PRNewswire/ -- Gradient Denervation Technologies, a Paris-based medical device company developing a minimally-invasive,...Gradient Denervation Technologies closes €14m Series A led by Sabadell Asabys
PARIS--(BUSINESS WIRE)--Gradient Denervation Technologies closes €14m Series A led by Sabadell Asabys. Thuja Capital and founding investor Sofinnova Partners joined the round
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Gradient Denervation Technologies
Sign Up For FreeTo access detailed company insights
Gradient Denervation Technologies is a Paris-based medical device company focused on developing a minimally invasive, ultrasound-based system for treating pulmonary hypertension, particularly in patients with left-sided heart disease. Their innovative Gradient Denervation System utilizes therapeutic ultrasound energy to ablate nerves around the pul... Read More
